Post-Stupp Protocol Surveillance for Glioblastoma Multiforme
Obtain a baseline contrast-enhanced MRI 3-4 weeks after completing radiotherapy, then perform clinical assessments with contrast-enhanced MRI every 2-3 months during the first 2 years, followed by less frequent imaging (every 3-6 months) thereafter if the patient remains stable. 1
Baseline Imaging After Treatment Completion
The EANO guidelines explicitly state that an MRI scan scheduled 3-4 weeks after completion of radiotherapy provides a new baseline to monitor the further course of disease 1. This timing is critical because:
- It allows acute radiation effects to stabilize
- It establishes a reference point for detecting true progression versus pseudoprogression
- It captures the immediate post-treatment tumor status before adjuvant temozolomide continues
Standard Surveillance Schedule
While the provided guidelines don't specify exact surveillance intervals in the excerpts, the standard practice based on clinical trial protocols (including the original Stupp protocol) involves:
During Adjuvant Temozolomide (Months 1-6 post-radiotherapy):
- Clinical assessment and contrast-enhanced MRI every 2-3 months (typically before each odd-numbered cycle of adjuvant TMZ)
- Monitor for pseudoprogression, which commonly occurs within the first 3 months after completing radiotherapy 2, 3
Post-Adjuvant Phase (After completing 6 cycles):
- MRI every 2-3 months for the first 2 years when recurrence risk is highest
- Every 3-6 months thereafter if stable, as 80-90% of recurrences occur within 2 cm of the irradiated field 3
Critical Surveillance Components
Clinical Assessment Should Include:
- Neurological examination for new deficits
- Performance status (Karnofsky score)
- Corticosteroid requirements (increasing needs may indicate progression)
- New seizure activity or changes in seizure control
MRI Protocol Requirements:
- Contrast-enhanced T1-weighted sequences (essential for detecting enhancing tumor)
- T2-weighted and FLAIR sequences (for non-enhancing tumor and edema)
- Pre- and post-contrast imaging to assess enhancement patterns 1
Common Pitfalls and How to Avoid Them
Pseudoprogression vs. True Progression
This is the most challenging diagnostic dilemma in GBM surveillance 2, 3. Pseudoprogression occurs in 20-30% of patients within the first 3 months after completing radiotherapy and can mimic tumor progression on conventional MRI.
Key distinguishing features:
- Pseudoprogression typically occurs within 12 weeks of completing radiotherapy
- More common in MGMT-methylated tumors (which respond better to treatment)
- May cause new symptoms due to mass effect and edema despite being treatment-related 2
When conventional MRI is indeterminate, consider:
- Advanced MRI techniques (perfusion imaging, MR spectroscopy) 4, 5
- Amino acid PET imaging (though not standard practice per guidelines) 1
- Close interval follow-up imaging (4-6 weeks) to assess stability
- Tissue diagnosis if clinical deterioration warrants intervention
Radiation Necrosis
Can occur months to years after radiotherapy and also mimics progression. The histologic admixture of tumor growth and treatment effects within the posttreatment bed further complicates interpretation 4.
Adjustments for Specific Populations
Elderly Patients (≥70 years):
The surveillance schedule should be similar, but recognize that these patients received modified treatment regimens (hypofractionated RT or TMZ monotherapy) 6. Their surveillance may be less intensive if performance status declines.
Poor Performance Status:
More frequent clinical assessments may be needed, but imaging frequency might be reduced if the patient is not a candidate for further intervention.
Evidence Quality Note
The EANO 2021 guidelines 1 provide the most authoritative and recent guidance, explicitly stating the 3-4 week post-RT baseline MRI timing. However, neither guideline provides granular surveillance interval recommendations in the excerpts provided. The 2-3 month surveillance intervals during and after adjuvant therapy represent standard practice derived from clinical trial protocols, including the original Stupp protocol design, rather than explicit guideline statements in these excerpts.
The emphasis on distinguishing pseudoprogression from true progression is well-supported across multiple recent sources 4, 5, 2, 3, highlighting this as the central challenge in post-Stupp surveillance that directly impacts clinical decision-making about continuing versus changing therapy.